Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.03 – $1.09
Volume52,222
Market cap$15M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$14.7M
Price / earnings
—
Price / book
1.75×
Price / sales
—
EV / sales
—
EV / EBITDA
0.04×
Profitability
Earnings per share
-$1.95
Return on assets
-148.79%
Return on equity
-310.94%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
1.87×
Quick ratio
1.87×
Cash ratio
1.73×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$25.03M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TVRD, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Revenue
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
Selling, general and administrative
$2.63M
$2.14M
$2.1M
$2.34M
$3.06M
Research and development
$4M
$4.91M
$5.49M
$3.6M
$5.81M
Total operating expenses
$6.63M
$7.05M
$7.59M
$5.94M
$8.87M
Operating income
-$6.63M
-$7.05M
-$7.59M
-$5.94M
-$8.87M
Interest expense
$0
$0
$0
$0
$0
Income before taxes
-$6.46M
-$6.8M
-$7.28M
-$5.53M
$4.17M
Income taxes
$0
$0
$0
$0
$0
Net income
-$6.46M
-$6.8M
-$7.28M
-$5.53M
$4.17M
Net income attributable to common shareholders
-$6.46M
-$6.8M
-$7.28M
-$5.53M
$4.17M
EBITDA
-$6.61M
-$7.03M
-$7.56M
-$5.91M
-$8.85M
Basic earnings per share
-$0.69
-$0.73
-$0.77
-$0.59
$0.51
Diluted earnings per share
-$0.69
-$0.73
-$0.68
-$0.59
-$1.00
Recent news
Company coverage with links to the original publishers.
Tvardi Therapeutics, a clinical-stage biopharmaceutical company developing STAT3-targeting therapies, announced it will present at Chardan's 10th Annual Healthcare Conference on October 20, 2026. The company is advancing TTI-109 for gastrointestinal diseases and TTI-101 in a Phase 1b/2 trial for hepatocellular carcinoma, with preclinical data supporting potential in ulcerative colitis treatment.
The idiopathic pulmonary fibrosis (IPF) treatment landscape is expanding with 80+ companies developing 100+ novel therapies across various clinical stages. Growing disease awareness and diagnostic improvements are driving demand for more effective treatments beyond current antifibrotic limitations. Key developments include orphan drug designations, positive clinical trial data, and FDA clinical hold lifts for several promising candidates in 2025-2026.
Tvardi Therapeutics (NASDAQ: TVRD) experienced an 80% stock decline on October 13, 2025, after disappointing preliminary data from its Phase 2 REVERT clinical trial of TTI-101 for idiopathic pulmonary fibrosis. The study failed to meet its primary goals regarding safety and lung function outcomes. A securities law firm is now investigating potential claims on behalf of affected investors.
Tvardi Therapeutics' stock plummeted over 80% on October 13, 2025, following disappointing preliminary data from its Phase 2 REVERT clinical trial of TTI-101 for idiopathic pulmonary fibrosis. The study failed to meet its primary goals regarding safety and efficacy outcomes. Securities law firm Faruqi & Faruqi is investigating potential claims on behalf of affected investors.
Tvardi Therapeutics experienced significant stock decline after disappointing Phase 2 clinical trial results for TTI-101 in idiopathic pulmonary fibrosis, with preliminary data showing the study did not meet its goals.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.